Can you provide a comprehensive overview of dengue, including its etiology, serotypes, clinical features, disease course, diagnosis, and treatment?

Comprehensive Overview of Dengue

Etiology

Dengue is caused by the dengue virus (DENV), a single-stranded RNA flavivirus transmitted primarily by day-biting Aedes aegypti mosquitoes, with Aedes albopictus as a secondary vector 1, 2. The virus exists as four antigenically distinct serotypes (DENV-1, DENV-2, DENV-3, and DENV-4), each capable of causing disease independently 3, 4. Infection with one serotype provides lifelong immunity to that specific serotype but only temporary cross-protection against others, making subsequent infections with different serotypes particularly dangerous due to antibody-dependent enhancement (ADE) 4.

The virus structure includes three structural proteins (capsid, membrane, and envelope) and seven non-structural proteins, with NS1 playing a critical role in pathogenesis through endothelial dysfunction 3, 4.

Geographic Distribution and Epidemiology

Dengue is endemic throughout the tropics, particularly in Asia and South America, with over 100 countries reporting cases and an annual global incidence of 50-100 million patients 1. It represents the most common arbovirus encountered in returning travelers and is a leading cause of fever in those returning from Asia 1. The disease burden has increased dramatically, with 5.2 million cases reported in 2019,70% occurring in Southeast Asia, the Western Pacific, and Asia 5.

Incubation Period

The incubation period ranges from 4-8 days (range: 3-14 days) after mosquito bite 1.

Clinical Features and Disease Spectrum

Classic Dengue Fever

The typical presentation includes acute febrile illness with frontal headache, retro-orbital pain, severe myalgia and arthralgia (particularly back pain—hence "breakbone fever"), and rash 6. The fever pattern is characteristically biphasic in some cases.

Disease Classification

According to the 2009 WHO classification, dengue presents in three forms 2:

• Dengue without warning signs (mild febrile illness)
• Dengue with warning signs (abdominal pain, persistent vomiting, fluid accumulation, mucosal bleeding, lethargy, liver enlargement, rising hematocrit with falling platelets)
• Severe dengue (with or without hemorrhage)

Severe Manifestations

Dengue Hemorrhagic Fever (DHF) is defined by 6:

• Acute febrile illness with bleeding phenomena (minor or major)
• Thrombocytopenia (≤100,000/mm³)
• Evidence of plasma leakage: hemoconcentration (hematocrit increased ≥20%) or objective evidence of increased capillary permeability

Dengue Shock Syndrome (DSS) includes all DHF criteria plus 6:

• Hypotension or narrow pulse pressure (≤20 mm Hg)
• Fluid loss and hypotensive shock

Important caveat: DHF and DSS are rare in travelers but more common in endemic populations, particularly with secondary infections 1.

Cardiac Complications

Cardiac involvement occurs in 12-50% of hospitalized patients and includes 2:

• Arrhythmias
• Pericarditis
• Myocarditis (may mimic myocardial infarction)
• Left ventricular systolic dysfunction
• Rarely: intracoronary thrombosis, coronary dissection, intramural hematoma

Men face higher risk of cardiac complications compared to women. Cardiac complications are more frequently reported in pediatric populations 2.

Disease Course

Most dengue infections are self-limiting over several days to weeks. The critical phase typically occurs around days 3-7 of illness when defervescence begins—this is when plasma leakage and hemorrhagic complications are most likely to develop. Any abnormality on echocardiography has been associated with adverse outcomes 2.

Laboratory Diagnosis

Timing-Based Diagnostic Algorithm

For specimens collected ≤7 days after symptom onset 1, 7, 8:

Primary test: PCR (NAAT) on serum, plasma, or whole blood

• Detects viral RNA during viremic period (days 1-6 after symptom onset)
• Most specific and sensitive during acute phase
• Positive result confirms acute dengue infection

Alternative: NS1 antigen detection

• Detectable from day 1 up to 10 days after symptom onset
• Acceptable alternative to NAAT for acute infection 8
• Can be performed on serum

For specimens collected >7 days after symptom onset 1, 7:

Primary test: IgM capture ELISA

• IgM antibodies appear 3-5 days after symptom onset in primary infection
• Remain detectable for 2-3 months 8
• Critical limitation: May not be detectable in secondary infections 8

Confirmatory testing: Plaque Reduction Neutralization Test (PRNT)

• Required when specific diagnosis is needed for clinical or epidemiologic purposes 7
• PRNT titer ≥10 against dengue with negative titers (<10) against Zika and other flaviviruses confirms recent dengue infection 7
• PRNT titer ≥10 for both dengue and Zika indicates recent flavivirus infection but cannot identify specific virus 7

Retrospective confirmation: IgG ELISA on convalescent serum at 3 weeks demonstrating seroconversion 1

Important Diagnostic Pitfalls

1. Cross-reactivity with other flaviviruses (West Nile, Zika, yellow fever, Japanese encephalitis, tick-borne encephalitis) is well recognized 1, 8. Always obtain vaccination history for interpretation.

2. In secondary dengue infections, IgM may be absent or minimal while IgG rises rapidly 8. Do not rule out dengue based solely on negative IgM in endemic populations.

3. Positive IgM without PRNT confirmation should be interpreted as "presumptive recent dengue infection" 7.

4. For indeterminate IgM results, repeat testing on the same specimen or perform PRNT 7.

Treatment

There is no specific antiviral treatment for dengue; management is entirely supportive 1. The focus is on:

Fluid Management

• Careful fluid resuscitation for plasma leakage
• Monitor hematocrit and platelet counts closely
• Avoid overhydration which can worsen outcomes

Monitoring for Warning Signs

• Daily complete blood counts
• Watch for signs of plasma leakage (rising hematocrit, falling platelets)
• Monitor for bleeding manifestations
• Assess for organ dysfunction

Symptomatic Treatment

• Acetaminophen for fever (avoid NSAIDs and aspirin due to bleeding risk)
• Antiemetics as needed
• Pain management

Hospitalization Criteria

Admit patients with:

• Warning signs (abdominal pain, persistent vomiting, fluid accumulation, mucosal bleeding, lethargy)
• Severe dengue (plasma leakage, severe bleeding, organ impairment)
• High-risk populations (infants, elderly, pregnant women, comorbidities)

Prevention Strategies

Vector control remains the primary prevention method 5:

• Elimination of mosquito breeding sites (standing water)
• Use of insect repellents containing DEET
• Protective clothing during daytime hours (when Aedes mosquitoes bite)
• Window screens and air conditioning
• Environmental interventions in endemic areas

Vaccination

The first licensed tetravalent vaccine (CYD-Dengvaxia) exists but is not approved in all countries and has limitations 4. Vaccine development is complicated by the need for balanced immune response against all four serotypes and the risk of ADE 5, 4. Vaccination status will influence serological test interpretation and requires algorithm adjustments 9.